RxAll
AI-powered drug authentication for Africa
About RxAll
RxAll is a pioneering healthtech company founded in 2016 that addresses one of Africa’s most critical healthcare challenges: counterfeit and substandard medications. Every year, approximately 1 million deaths globally are attributed to fake drugs, with Africa bearing a disproportionate burden of this crisis. Founded by Yale University graduates Adebayo Alonge, Amy Kao, and Wei Liu, RxAll emerged from personal tragedy—Alonge nearly lost his life to counterfeit salbutamol tablets in Nigeria in 2005. This experience fueled the team’s mission to create innovative solutions that ensure universal access to safe, high-quality medicines.
At the core of RxAll’s technology suite is the RxScanner, a patented handheld drug authentication device that uses AI-enabled spectroscopy to analyze a drug’s molecular fingerprint and verify its authenticity in real-time. With 99.9% accuracy, the scanner works offline and delivers results within 20 seconds via a mobile app, making it accessible for hospitals, pharmacies, regulatory agencies, and even patients. The device employs advanced deep learning algorithms to compare spectral signatures against a comprehensive database, instantly detecting counterfeits without destroying the medication. This groundbreaking innovation has been adopted in pilot programs across Nigeria, Kenya, Uganda, and India, earning recognition from drug regulatory agencies worldwide.
Beyond drug authentication, RxAll has evolved into a comprehensive digital infrastructure platform for healthcare. The company operates RxDelivered, an online marketplace that connects hospitals and pharmacies with verified wholesalers and pharmaceutical companies, enabling access to batch quality-certified medicines at manufacturer prices. RxPOS, their pharmacy management software, helps retailers automate operations and sell inventory both in-store and online. Additionally, RxPay, their embedded fintech solution, provides invoice financing to ensure affordability and availability of quality medicines. Having raised over $3.15 million in funding from investors including Launch Africa and HAX (SOSV), RxAll is scaling its operations across West and East Africa, tackling a $1.25 trillion global problem of access to affordable, safe drugs while building the future of pharmaceutical distribution on the continent.
Discussion
Product Demo Video
Investors
-
L
Launch Africa
Seed funding round
-
H
HAX (SOSV)
$3.15M funding round
People
-
A
Adebayo Alonge
CEO and Co-Founder of RxAll. Yale and Harvard-trained entrepreneur with over 15 years of experience scaling multimillion-dollar businesses in fintech and healthtech.
- 2x founder and CEOnRaised over $11M in fundingnGlobal pioneer in combating counterfeit medicines using AI
-
A
Amy Kao
Co-Founder of RxAll. Yale University graduate who co-founded RxAll to combat counterfeit medications in Africa.
- Co-Founder of RxAllnYale University graduatenPioneered drug authentication technology
-
W
Wei Liu
Co-Founder of RxAll. Scientist, innovator, and entrepreneur focused on deep tech solutions for healthcare.
- Co-Founder of RxAllnScientist and InnovatornDeep tech healthcare entrepreneur
-
S
Sokunbi Kayode
Strategic Financial & Risk Analyst at RxAll with 15+ years in microfinance and lending, specializing in Power BI and data analytics.
- Strategic Financial & Risk Analystn15+ years in microfinance & lendingnPower BI and data analytics expert